
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/958521/publications.pdf Version: 2024-02-01



ROBERT LYOUNG

#	Article	IF	CITATIONS
1	Radiomic Analysis to Predict Histopathologically Confirmed Pseudoprogression in Glioblastoma Patients. Advances in Radiation Oncology, 2023, 8, 100916.	1.2	6
2	[89Zr]Zr-huJ591 immuno-PET targeting PSMA in IDH mutant anaplastic oligodendroglioma. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 783-785.	6.4	4
3	Semisupervised Training of a Brain MRI Tumor Detection Model Using Mined Annotations. Radiology, 2022, 303, 80-89.	7.3	7
4	Quantitative assessment of circulating tumor cells in cerebrospinal fluid as a clinical tool to predict survival in leptomeningeal metastases. Journal of Neuro-Oncology, 2022, 157, 81-90.	2.9	16
5	Deep Learning Achieves Neuroradiologist-Level Performance in Detecting Hydrocephalus Requiring Treatment. Journal of Digital Imaging, 2022, 35, 1662-1672.	2.9	1
6	Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis. Journal of Clinical Oncology, 2022, 40, 3858-3867.	1.6	47
7	Clinical trial of proton craniospinal irradiation for leptomeningeal metastases. Neuro-Oncology, 2021, 23, 134-143.	1.2	56
8	Integrating Eye Tracking and Speech Recognition Accurately Annotates MR Brain Images for Deep Learning: Proof of Principle. Radiology: Artificial Intelligence, 2021, 3, e200047.	5.8	10
9	Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. Journal of Clinical Oncology, 2021, 39, 30-37.	1.6	239
10	Multiband diffusion tensor imaging for presurgical mapping of motor and language pathways in patients with brain tumors. Journal of Neuroimaging, 2021, 31, 784-795.	2.0	1
11	Positron emission tomography and magnetic resonance imaging in primary central nervous system lymphoma—a narrative review. Annals of Lymphoma, 2021, 5, 15-15.	4.5	13
12	The effect of surgery on radiation necrosis in irradiated brain metastases: extent of resection and long-term clinical and radiographic outcomes. Journal of Neuro-Oncology, 2021, 153, 507-518.	2.9	20
13	Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial. Clinical Cancer Research, 2021, 27, 4491-4499.	7.0	112
14	Synergism of Checkpoint Inhibitors and Peptide Receptor Radionuclide Therapy in the Treatment of Pituitary Carcinoma. Journal of the Endocrine Society, 2021, 5, bvab133.	0.2	21
15	SURG-03. The effect of surgery on radiation necrosis in irradiated brain metastases: extent of resection and long-term clinical and radiographic outcomes. Neuro-Oncology Advances, 2021, 3, iii23-iii24.	0.7	0
16	IDH glioma radiogenomics in the era of deep learning. Neuro-Oncology, 2021, 23, 182-183.	1.2	8
17	Salvage resection of recurrent previously irradiated brain metastases: tumor control and radiation necrosis dependency on adjuvant re-irradiation. Journal of Neuro-Oncology, 2021, 155, 277-286.	2.9	16
18	Diffusion and Perfusion MRI Predicts Response Preceding and Shortly After Radiosurgery to Brain Metastases: A Pilot Study. Journal of Neuroimaging, 2021, 31, 317-323.	2.0	14

#	Article	IF	CITATIONS
19	Quantitative cerebrospinal fluid circulating tumor cells are a potential biomarker of response for proton craniospinal irradiation for leptomeningeal metastasis. Neuro-Oncology Advances, 2021, 3, vdab181.	0.7	8
20	18F-Fluorocholine PET uptake correlates with pathologic evidence of recurrent tumor after stereotactic radiosurgery for brain metastases. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1446-1457.	6.4	13
21	DCE-MRI perfusion predicts pseudoprogression in metastatic melanoma treated with immunotherapy. Journal of Neuro-Oncology, 2020, 146, 339-346.	2.9	17
22	Preclinical and first-in-human-brain-cancer applications of [18F]poly (ADP-ribose) polymerase inhibitor PET/MR. Neuro-Oncology Advances, 2020, 2, vdaa119.	0.7	14
23	Lorlatinib and Bevacizumab Activity in <i>ALK-</i> Rearranged Lung Cancers After Lorlatinib Progression. JCO Precision Oncology, 2020, 4, 1333-1338.	3.0	9
24	Diagnosing spinal cord ischemia. Neurology: Clinical Practice, 2020, 10, 469-470.	1.6	0
25	Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic <i>EGFR</i> -Mutant Lung Cancers. JAMA Oncology, 2020, 6, 1048.	7.1	96
26	Ivosidenib in Isocitrate Dehydrogenase 1 <i>–</i> Mutated Advanced Glioma. Journal of Clinical Oncology, 2020, 38, 3398-3406.	1.6	167
27	Magnetic resonance spectroscopic imaging in gliomas: clinical diagnosis and radiotherapy planning. BJR Open, 2020, 2, 20190026.	0.6	13
28	Computational Modeling of Interstitial Fluid Pressure and Velocity in Non-small Cell Lung Cancer Brain Metastases Treated With Stereotactic Radiosurgery. Frontiers in Neurology, 2020, 11, 402.	2.4	9
29	Value of [18F]-FDG positron emission tomography in patients with recurrent glioblastoma receiving bevacizumab. Neuro-Oncology Advances, 2020, 2, vdaa050.	0.7	3
30	Prognostic and radiographic correlates of a prospectively collected molecularly profiled cohort of IDH1/2 â€wildtype astrocytomas. Brain Pathology, 2020, 30, 653-660.	4.1	3
31	Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment. Neuro-Oncology, 2020, 22, 1822-1830.	1.2	23
32	Larotrectinib Demonstrates CNS Efficacy in TRK Fusion-Positive Solid Tumors. JCO Precision Oncology, 2019, 3, 1-5.	3.0	15
33	Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. Clinical Cancer Research, 2019, 25, 5537-5547.	7.0	107
34	Impact of image preprocessing on the scanner dependence of multi-parametric MRI radiomic features and covariate shift in multi-institutional glioblastoma datasets. Physics in Medicine and Biology, 2019, 64, 165011.	3.0	79
35	MRI radiomic features are associated with survival in melanoma brain metastases treated with immune checkpoint inhibitors. Neuro-Oncology, 2019, 21, 1578-1586.	1.2	42
36	Frequency and outcomes of brain metastases in patients with <i>HER2</i> â€mutant lung cancers. Cancer, 2019, 125, 4380-4387.	4.1	51

#	Article	IF	CITATIONS
37	Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature, 2019, 565, 654-658.	27.8	361
38	Reliability of tumor segmentation in glioblastoma: Impact on the robustness of MRIâ€radiomic features. Medical Physics, 2019, 46, 3582-3591.	3.0	38
39	Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCEâ€MRI derived biomarkers in multicenter oncology trials. Journal of Magnetic Resonance Imaging, 2019, 49, i.	3.4	5
40	Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature, 2019, 567, 521-524.	27.8	222
41	Preoperative MRI-radiomics features improve prediction of survival in glioblastoma patients over MGMT methylation status alone. Oncotarget, 2019, 10, 660-672.	1.8	35
42	MR Perfusion and MR Spectroscopy of Brain Neoplasms. Radiologic Clinics of North America, 2019, 57, 1177-1188.	1.8	17
43	Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCEâ€MRI derived biomarkers in multicenter oncology trials. Journal of Magnetic Resonance Imaging, 2019, 49, e101-e121.	3.4	241
44	Clinicopathologic and genomic characterization of parenchymal brain metastases (BM) in prostate cancer (PCa) Journal of Clinical Oncology, 2019, 37, 227-227.	1.6	1
45	Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro-Oncology, 2018, 20, 1240-1250.	1.2	64
46	Background, current role, and potential applications of radiogenomics. Journal of Magnetic Resonance Imaging, 2018, 47, 604-620.	3.4	137
47	Diffusion Tensor Imaging Shows Corpus Callosum Differences between Highâ€Grade Gliomas and Metastases. Journal of Neuroimaging, 2018, 28, 199-205.	2.0	5
48	Twice weekly pulse and daily continuousâ€dose erlotinib as initial treatment for patients with epidermal growth factor receptor–mutant lung cancers and brain metastases. Cancer, 2018, 124, 105-109.	4.1	25
49	Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas. Journal of Clinical Oncology, 2018, 36, 1702-1709.	1.6	39
50	Genomic Heterogeneity Underlies Mixed Response to Tropomyosin Receptor Kinase Inhibition in Recurrent Glioma. JCO Precision Oncology, 2018, 2, 1-6.	3.0	2
51	Discriminating radiation injury from recurrent tumor with [18F]PARPi and amino acid PET in mouse models. EJNMMI Research, 2018, 8, 59.	2.5	16
52	Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3925-3930.	3.6	106
53	Pretreatment dynamic contrast-enhanced MRI biomarkers correlate with progression-free survival in primary central nervous system lymphoma. Journal of Neuro-Oncology, 2018, 140, 351-358.	2.9	21
54	Resting-State Functional Magnetic Resonance Imaging and Probabilistic Diffusion Tensor Imaging Demonstrate That the Greatest Functional and Structural Connectivity in the Hand Motor Homunculus Occurs in the Area of the Thumb. Brain Connectivity, 2018, 8, 371-379.	1.7	6

#	Article	IF	CITATIONS
55	"Comment on Hatzoglou et al.: Dynamic contrast-enhanced MRI perfusion vs 18FDG PET/CT in differentiating brain tumor progression from radiation injury―Reply. Neuro-Oncology, 2017, 19, now286.	1.2	0
56	Teaching Neuro <i>Images</i> : Diagnosis. Neurology, 2017, 88, e157.	1.1	1
57	Regarding "Computer-Extracted Texture Features to Distinguish Cerebral Radionecrosis from Recurrent Brain Tumors on Multiparametric MRI: A Feasibility Study― American Journal of Neuroradiology, 2017, 38, E18-E19.	2.4	2
58	Predictive modeling of outcomes following definitive chemoradiotherapy for oropharyngeal cancer based on FDG-PET image characteristics. Physics in Medicine and Biology, 2017, 62, 5327-5343.	3.0	51
59	Imaging characteristics associated with clinical outcomes in posterior reversible encephalopathy syndrome. Neuroradiology, 2017, 59, 379-386.	2.2	68
60	Diagnostic Accuracy of T1-Weighted Dynamic Contrast-Enhanced–MRI and DWI-ADC for Differentiation of Glioblastoma and Primary CNS Lymphoma. American Journal of Neuroradiology, 2017, 38, 485-491.	2.4	71
61	Corticosteroid therapy and severity of vasogenic edema in posterior reversible encephalopathy syndrome. Journal of the Neurological Sciences, 2017, 380, 11-15.	0.6	43
62	Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma. International Journal of Radiation Oncology Biology Physics, 2017, 99, 797-804.	0.8	40
63	Comparison of compressed sensing diffusion spectrum imaging and diffusion tensor imaging in patients with intracranial masses. Magnetic Resonance Imaging, 2017, 36, 24-31.	1.8	13
64	Marginal zone dural lymphoma: the Memorial Sloan Kettering Cancer Center and University of Miami experiences. Leukemia and Lymphoma, 2017, 58, 882-888.	1.3	34
65	Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment. , 2017, 5, 76.		96
66	A phase 1 study of osimertinib and bevacizumab as initial treatment for patients with EGFR-mutant lung cancers Journal of Clinical Oncology, 2017, 35, 9033-9033.	1.6	6
67	Pulse-continuous dose erlotinib as initial targeted therapy for patients with <i>EGFR</i> -mutant lung cancers with untreated brain metastases Journal of Clinical Oncology, 2017, 35, 9039-9039.	1.6	1
68	Corpus Callosum Diffusion and Language Lateralization in Patients with Brain Tumors: A DTI and fMRI Study. Journal of Neuroimaging, 2016, 26, 224-231.	2.0	22
69	Comparison of Glioblastomas and Brain Metastases using Dynamic Contrastâ€Enhanced Perfusion MRI. Journal of Neuroimaging, 2016, 26, 240-246.	2.0	46
70	Conventional and Advanced Imaging of Diffuse Intrinsic Pontine Glioma. Journal of Child Neurology, 2016, 31, 1386-1393.	1.4	29
71	Infiltration of the basal ganglia by brain tumors is associated with the development of co-dominant language function on fMRI. Brain and Language, 2016, 155-156, 44-48.	1.6	12
72	A Novel Methodology for Applying Multivoxel MR Spectroscopy to Evaluate Convection-Enhanced Drug Delivery in Diffuse Intrinsic Pontine Gliomas. American Journal of Neuroradiology, 2016, 37, 1367-1373.	2.4	5

#	Article	IF	CITATIONS
73	TTFields Therapy. , 2016, , 243-256.		2
74	Aicardi Syndrome. Ophthalmology, 2016, 123, 1645.	5.2	1
75	A novel magnetic resonance imaging segmentation technique for determining diffuse intrinsic pontine glioma tumor volume. Journal of Neurosurgery: Pediatrics, 2016, 18, 565-572.	1.3	12
76	Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients. Neuro-Oncology, 2016, 18, 735-743.	1.2	28
77	A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation. Neuro-Oncology, 2016, 18, 873-880.	1.2	72
78	Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. Neuro-Oncology, 2016, 18, 283-290.	1.2	161
79	Nonenhancing Leptomeningeal Metastases. Neurohospitalist, The, 2016, 6, 24-28.	0.8	19
80	Phase IB trial of carboxyamidotriazole orotate (CTO) and radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ) in newly diagnosed glioblastoma (GBM) Journal of Clinical Oncology, 2016, 34, 2060-2060.	1.6	0
81	Weekly response assessment of involved lymph nodes to radiotherapy using diffusion-weighted MRI in oropharynx squamous cell carcinoma. Medical Physics, 2015, 43, 137-147.	3.0	18
82	Dynamic Contrastâ€Enhanced Perfusion MRI and Diffusionâ€Weighted Imaging in Grading of Gliomas. Journal of Neuroimaging, 2015, 25, 792-798.	2.0	66
83	T1-Weighted Dynamic Contrast-Enhanced MRI as a Noninvasive Biomarker of Epidermal Growth Factor Receptor vIII Status. American Journal of Neuroradiology, 2015, 36, 2256-2261.	2.4	46
84	Ipilimumab and whole brain radiation therapy for melanoma brain metastases. Journal of Neuro-Oncology, 2015, 121, 159-165.	2.9	53
85	Diffusion and Perfusion MRI to Differentiate Treatment-Related Changes Including Pseudoprogression from Recurrent Tumors in High-Grade Gliomas with Histopathologic Evidence. American Journal of Neuroradiology, 2015, 36, 877-885.	2.4	151
86	Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma. Journal of Neuro-Oncology, 2015, 125, 183-190.	2.9	106
87	Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases. Journal of Neuro-Oncology, 2015, 125, 149-156.	2.9	224
88	Identification of the Corticobulbar Tracts of the Tongue and Face Using Deterministic and Probabilistic DTI Fiber Tracking in Patients with Brain Tumor. American Journal of Neuroradiology, 2015, 36, 2036-2041.	2.4	30
89	Hypertrophic olivary degeneration resulting from posterior fossa masses and their treatments. Clinical Imaging, 2015, 39, 787-790.	1.5	12
90	Extraneural metastases of medulloblastoma: Desmoplastic variants may have prolonged survival. Pediatric Blood and Cancer, 2015, 62, 611-615.	1.5	11

#	Article	IF	CITATIONS
91	Pretreatment Dynamic Susceptibility Contrast MRI Perfusion in Glioblastoma: Prediction of EGFR Gene Amplification. Clinical Neuroradiology, 2015, 25, 143-150.	1.9	59
92	Abstract 1498: Feasibility of 2-hydroxyglutarate 1H-MR spectroscopy for routine clinical glioma imaging. Cancer Research, 2015, 75, 1498-1498.	0.9	1
93	Phase IB trial of carboxyamidotriazole orotate (CTO) and radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ) in newly diagnosed glioblastoma (GBM) Journal of Clinical Oncology, 2015, 33, 2062-2062.	1.6	7
94	Cranial Nerves. Medical Radiology, 2014, , 167-203.	0.1	0
95	Diffusion Tensor Imaging and Tractography of the Corticospinal Tract in the Presence of Enlarged Virchow–Robin Spaces. Journal of Neuroimaging, 2014, 24, 79-82.	2.0	14
96	Brain Metastases from Prostate Cancer: An 11‥ear Analysis in the MRI Era with Emphasis on Imaging Characteristics, Incidence, and Prognosis. Journal of Neuroimaging, 2014, 24, 161-166.	2.0	72
97	Adult Brain Tumor Imaging: State of the Art. Seminars in Roentgenology, 2014, 49, 39-52.	0.6	21
98	Clioblastoma-arteriovenous fistula complex: imaging characteristics and treatment considerations. Clinical Imaging, 2014, 38, 187-190.	1.5	5
99	Probabilistic fiber tracking of the language and motor white matter pathways of the supplementary motor area (SMA) in patients with brain tumors. Journal of Neuroradiology, 2014, 41, 342-349.	1.1	10
100	Intramedullary spinal cord and leptomeningeal metastases from intracranial low-grade oligodendroglioma. Clinical Imaging, 2014, 38, 505-507.	1.5	3
101	Moderately Elevated Intracranial Pressure Produces Greater Cross-Filling of the Anterior Communicating Artery. Neuroradiology Journal, 2014, 27, 401-408.	1.2	0
102	Clinical characteristics and outcomes of patients with prostate cancer and parenchymal brain metastases (PBM) Journal of Clinical Oncology, 2014, 32, 187-187.	1.6	0
103	Correlation of planned dose to area postrema and dorsal vagal complex with clinical symptoms of nausea and vomiting in oropharyngeal cancer (OPC) patients treated with radiation alone using IMRT. Journal of Radiation Oncology, 2013, 2, 407-412.	0.7	7
104	Role of MRI perfusion in improving the treatment of brain tumors. Imaging in Medicine, 2013, 5, 407-426.	0.0	9
105	MRI perfusion in determining pseudoprogression in patients with glioblastoma. Clinical Imaging, 2013, 37, 41-49.	1.5	119
106	Comparison of the effectiveness of MRI perfusion and fluorine-18 FDG PET-CT for differentiating radiation injury from viable brain tumor: a preliminary retrospective analysis with pathologic correlation in all patients. Clinical Imaging, 2013, 37, 451-457.	1.5	28
107	Bevacizumab as a treatment for radiation necrosis of brain metastases post stereotactic radiosurgery. Neuro-Oncology, 2013, 15, 1257-1263.	1.2	146
108	Diffusion-Weighted MR Imaging and MGMT Methylation Status in Glioblastoma: A Reappraisal of the Role of Preoperative Quantitative ADC Measurements. American Journal of Neuroradiology, 2013, 34, E10-E11.	2.4	21

ROBERT J YOUNG

#	Article	IF	CITATIONS
109	Potential Role of Preoperative Conventional MRI Including Diffusion Measurements in Assessing Epidermal Growth Factor Receptor Gene Amplification Status in Patients with Glioblastoma. American Journal of Neuroradiology, 2013, 34, 2271-2277.	2.4	36
110	Variability in the position of the retropharyngeal internal carotid artery. Laryngoscope, 2013, 123, 401-403.	2.0	21
111	Posterior Displacement of the Motor Blood Oxygen Levelâ€Dependent Functional MRI Signal into the Postcentral Gyrus in Patients with Preoperative Brain Tumor and Healthy Volunteers: Practical Guidelines to Correctly Interpret Functional MRI Findings. Neurographics, 2013, 3, 52-59.	0.1	4
112	Radiation therapy for breast cancer (BC) with central nervous system (CNS) metastases: A contemporary experience at Memorial Sloan-Kettering Cancer Center (MSKCC) Journal of Clinical Oncology, 2013, 31, 144-144.	1.6	1
113	Diffusion tensor tractography of the arcuate fasciculus in patients with brain tumors: Comparison between deterministic and probabilistic models. Journal of Biomedical Science and Engineering, 2013, 06, 192-200.	0.4	36
114	An Unusual Cause of Isolated Vomiting. Neurology, 2012, 78, 72-73.	1.1	2
115	Somatotopic Organization of Motor Pathways in the Internal Capsule: A Probabilistic Diffusion Tractography Study. American Journal of Neuroradiology, 2012, 33, 1274-1280.	2.4	52
116	Ruptured dermoid cyst arising from Meckel cave. Neurology: Clinical Practice, 2012, 2, 83-84.	1.6	1
117	Continuing the search for MR imaging biomarkers for MGMT promoter methylation status: conventional and perfusion MRI revisited. Neuroradiology, 2012, 54, 641-643.	2.2	21
118	Collision in the inferior olive: hypertrophic olivary degeneration complicated by radiation necrosis in brainstem primitive neuroendocrine tumor. Clinical Imaging, 2012, 36, 371-374.	1.5	5
119	Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma. Neurology, 2011, 76, 1918-1924.	1.1	167
120	Sphenoid Masses in Children: Radiologic Differential Diagnosis with Pathologic Correlation. American Journal of Neuroradiology, 2011, 32, 617-626.	2.4	23
121	Supraglottic Larynx and Hypopharynx: An Important Anatomic Distinction. Radiographics, 2011, 31, 116-116.	3.3	2
122	Isolated Diffusion Restriction Precedes the Development of Enhancing Tumor in a Subset of Patients with Glioblastoma. American Journal of Neuroradiology, 2011, 32, 1301-1306.	2.4	74
123	Hemangioma of the cavernous sinus in a child. Neurology, 2011, 77, 1647-1648.	1.1	4
124	Common and unusual craniofacial manifestations of metastatic neuroblastoma. Neuroradiology, 2010, 52, 549-553.	2.2	21
125	Imaging of Metastatic CNS Neuroblastoma. American Journal of Roentgenology, 2010, 194, 1223-1229.	2.2	53
126	Advanced Imaging in Brain Tumor Surgery. Neuroimaging Clinics of North America, 2010, 20, 311-335.	1.0	21

#	Article	IF	CITATIONS
127	Imaging of Brain Tumors: Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging. Neuroimaging Clinics of North America, 2010, 20, 379-400.	1.0	45
128	Imaging of Lymphoma of the Central Nervous System, Spine, and Orbit. Radiologic Clinics of North America, 2008, 46, 339-361.	1.8	68
129	Gliomas: Predicting Time to Progression or Survival with Cerebral Blood Volume Measurements at Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging. Radiology, 2008, 247, 490-498.	7.3	466
130	Comparison of region-of-interest analysis with three different histogram analysis methods in the determination of perfusion metrics in patients with brain gliomas. Journal of Magnetic Resonance Imaging, 2007, 26, 1053-1063.	3.4	80
131	Brain MRI: Tumor evaluation. Journal of Magnetic Resonance Imaging, 2006, 24, 709-724.	3.4	76
132	Neuroimaging of Metastatic Brain Disease. Neurosurgery, 2005, 57, S4-10-S4-23.	1.1	25
133	Lesion size determines accuracy of thallium-201 brain single-photon emission tomography in differentiating between intracranial malignancy and infection in AIDS patients. American Journal of Neuroradiology, 2005, 26, 1973-9.	2.4	20